JP2013529600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529600A5 JP2013529600A5 JP2013514392A JP2013514392A JP2013529600A5 JP 2013529600 A5 JP2013529600 A5 JP 2013529600A5 JP 2013514392 A JP2013514392 A JP 2013514392A JP 2013514392 A JP2013514392 A JP 2013514392A JP 2013529600 A5 JP2013529600 A5 JP 2013529600A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- asp
- ala
- pharmaceutical composition
- peptide derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 108090000190 Thrombin Proteins 0.000 claims description 22
- 229960004072 thrombin Drugs 0.000 claims description 22
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 10
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 239000000539 dimer Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 150000001408 amides Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 4
- 230000005855 radiation Effects 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 3
- 108091036078 conserved sequence Proteins 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- DVUFTQLHHHJEMK-IMJSIDKUSA-N Asp-Ala Chemical group OC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O DVUFTQLHHHJEMK-IMJSIDKUSA-N 0.000 claims 1
- 108090000371 Esterases Proteins 0.000 claims 1
- IEHDJWSAXBGJIP-RYUDHWBXSA-N Phe-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 IEHDJWSAXBGJIP-RYUDHWBXSA-N 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 108010084572 phenylalanyl-valine Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 108020002447 serine esterase Proteins 0.000 claims 1
- 102000005428 serine esterase Human genes 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35406710P | 2010-06-11 | 2010-06-11 | |
| US61/354,067 | 2010-06-11 | ||
| PCT/US2011/040006 WO2011156729A2 (en) | 2010-06-11 | 2011-06-10 | Methods of mitigating effects of radiation and reducing the risk of systemic infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013529600A JP2013529600A (ja) | 2013-07-22 |
| JP2013529600A5 true JP2013529600A5 (enExample) | 2014-07-17 |
Family
ID=44533067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013514392A Withdrawn JP2013529600A (ja) | 2010-06-11 | 2011-06-10 | 放射の影響を軽減し、及び全身性感染症のリスクを減少させる方法 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP2579891A2 (enExample) |
| JP (1) | JP2013529600A (enExample) |
| AU (1) | AU2011265228A1 (enExample) |
| CA (1) | CA2802176A1 (enExample) |
| WO (1) | WO2011156729A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021207411A1 (en) * | 2020-04-07 | 2021-10-14 | Chrysalis Biotherapeutics | Tp508 acute therapy for patients with respiratory virus infection |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| EP1539800B1 (en) | 2002-07-02 | 2007-05-23 | Orthologic Corp. | Thrombin peptide derivative dimers |
| AU2003256343B2 (en) | 2002-07-02 | 2006-12-21 | Orthologic Corp. | Thrombin peptide derivatives |
| US7294596B2 (en) | 2005-03-14 | 2007-11-13 | Diamorph Ceramic Ab | Sintered ceramic material with improved properties and method for its manufacturing |
| CA2663547C (en) * | 2006-09-22 | 2020-08-25 | Orthologic Corp. | Method of treating endothelial dysfunction |
| WO2008124172A1 (en) * | 2007-04-10 | 2008-10-16 | The Board Of Regents, The University Of Texas System | Combination therapy for chronic dermal ulcers |
-
2011
- 2011-06-10 CA CA2802176A patent/CA2802176A1/en not_active Abandoned
- 2011-06-10 EP EP11728735.9A patent/EP2579891A2/en not_active Withdrawn
- 2011-06-10 AU AU2011265228A patent/AU2011265228A1/en not_active Abandoned
- 2011-06-10 WO PCT/US2011/040006 patent/WO2011156729A2/en not_active Ceased
- 2011-06-10 JP JP2013514392A patent/JP2013529600A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102285377B1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 | |
| US10245297B2 (en) | Inhibitors of mitochondrial fission and methods of use thereof | |
| JP2015504052A5 (enExample) | ||
| JP2015509950A5 (enExample) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2010536333A5 (enExample) | ||
| JP2011528332A (ja) | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 | |
| JP2014506450A5 (enExample) | ||
| IN2012DN02981A (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2019533722A5 (enExample) | ||
| JP2019525753A5 (enExample) | ||
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| CA2839298C (en) | Anti-inflammatory pharmaceutical products | |
| O’Reilly et al. | Angiotensin-converting enzyme defines matrikine-regulated inflammation and fibrosis | |
| JP2004538320A5 (enExample) | ||
| JP2012516693A5 (enExample) | ||
| JP2011528334A (ja) | 哺乳動物のベータ・ディフェンシンを用いた、関節リウマチの治療 | |
| JP2006514822A5 (enExample) | ||
| KR102700862B1 (ko) | apoC-II 모방 펩타이드 | |
| WO2010103515A3 (en) | Compositions and methods for prevention and treatment of neurodegenerative diseases | |
| EP4028038A1 (en) | Peptide-based compositions and methods for treating alzheimer's disease | |
| JP2019038772A5 (enExample) | ||
| JP2013529600A5 (enExample) | ||
| KR20210010931A (ko) | 집먼지진드기 알레르기의 치료 및 예방 |